KMBC: Worldwide clinical drug trial for COVID-19 led by a doctor at Saint Luke's

In the search for a treatment for COVID-19, there is a worldwide clinical drug trial led by a doctor at Saint Luke's. Dr. Mikhail Kosiborod, of Saint Luke's Mid-America Heart Institute, is the principal investigator in a new clinical trial of the drug, often referred to as DAPA.

"The idea is you protect the vital organs, you prevent the disease from becoming more severe and thereby prevent development of severe complications and death. That's the premise behind the study," Kosiborod said.

The worldwide clinical trial will involve 900 COVID-19 patients, including some already enrolled in Kansas City. Each of the patients is currently hospitalized with the virus but not critical enough to be in the intensive care unit.

Kosiborod said the start-up time for this research is the fastest he's ever seen because the need is so urgent.

"The pandemic and the crisis is on everybody's mind and everybody in the scientific community, including clinical scientists like myself, want to get answers as quickly as possible," said Kosiborod. 

Once all 900 patients are enrolled, the follow-up period is 30 days. If DAPA proves to be safe and effective against the virus, researchers believe it could still be approved for use during this pandemic.

Related Content

Blue sphere COVID-19 viruses
Apr. 25, 2020

Kansas City Business Journal: Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious COVID-19 complications

Saint Luke's Mid America Heart Institute and drug company AstraZeneca PLC are conducting a clinical trial to see if a drug now used to treat diabetes could help prevent deadly complications in COVID-19 patients.
KCTV: Saint Luke’s Launches Global Clinical Trial to Investigate Potential COVID-19 Treatment
Apr. 25, 2020

KCTV: Saint Luke’s Launches Global Clinical Trial to Investigate Potential COVID-19 Treatment

As the entire world comes together to attempt to find a vaccine and treatments for this global pandemic, it is exciting that an international trial of this nature was created and is being led by doctors and researchers here in Kansas City.
stock image of hospitalized patient and doctor from Endocrine Today
Apr. 24, 2020

Endocrine Today: Clinical trial investigates dapagliflozin for COVID-19 treatment

Dr. Mikhail Kosiborod, principal investigator for DARE-19, talked to Healio: Endocrine Today about the new trial initiated by Saint Luke's Mid America Heart Institute and AstraZeneca.